Global Health Exhibition sees final agreement to localize insulin production

The signing of the agreement

The Global Health Exhibition 2024 witnessed today, Oct. 22, the signing of a final agreement to localize the production of some insulin products, in partnership with National Unified Procurement Co. (NUPCO), Sudair Pharmaceutical Co., French Sanofi and Denmark-based Novo Nordisk.

The agreement included the localization of six to seven items of insulin products, which reflects Saudi Arabia’s efforts to enhance its productive capabilities and its commitment to creating an attractive investment environment, which boosts its position as a regional center for pharmaceutical industries in line with its goals, the Saudi Press Agency reported.

The agreement seeks to enhance the government efforts, represented by the ministries of Health, Investment, and Industry and Mineral Resources in the localization of the medical and pharmaceutical industry. This comes in a way that contributes to achieving pharmaceutical and health security in the Kingdom and enhancing its leadership in this field, in line with its needs and medicine requirements, at a time when the sector is witnessing a transformation phase aimed at improving healthcare quality.

The Global Health Exhibition lured investments worth SAR 50 billion to contribute to addressing global health challenges and raising the level of citizen health.